A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Clinical needs of patients with disabilities are seen with the “medical gaze,” a depersonalized lens of evidence-based medicine and of presumed objectivity.
AMA J Ethics. 2023;25(1):E85-87. doi:
10.1001/amajethics.2023.85.
Dr Isa Ryan joins Ethics Talk to discuss her article, coauthored with Dr Ashish Premkumar and Professor Katie Watson: “Why the Post-Roe Era Requires Protecting Conscientious Provision as We Protect Conscientious Refusal in Health Care.”
Clinicians in Catholic health care institutions cannot prescribe contraceptives for pregnancy prevention under a false diagnosis without committing fraud and contravening doctrine. Referrals are one option the authors consider for navigating patient requests for contraception.
AMA J Ethics. 2018;20(7):E630-636. doi:
10.1001/amajethics.2018.630.
This narrative information graphic contextualizes the lack of current maternal morbidity and mortality data in the United States since the Dobbs v Jackson Women’s Health Organization decision in 2022.
AMA J Ethics. 2024;26(1):E92-93. doi:
10.1001/amajethics.2024.92.
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.